The Dairy Goat Co-operative has 55 farmer shareholders across Waikato and Taranaki, 240 staff in Hamilton, and now a Chicago private equity partner backing a push into China and the United States. It is the kind of deal more New Zealand exporters should be studying. The co-op gets growth capital, its farmers keep ownership, and the money goes into specialised nutrition sold into large, high-value markets.
This is a good-news story, and it should be read as one.
Capital without surrendering the co-op
The partner is AGR Partners. The deal size is commercially sensitive, but chief executive Alastair Hulbert was clear on the non-negotiable. “One of our main pre-requisites for getting the capital in is that we didn’t want to change the co-operative structure,” he told RNZ, adding that the money lets DGC “build faster in those markets without having to compromise returns to our farmers.”
The investment effectively closes DGC’s $40 million “Formula for Success” raise, and AGR’s own numbers explain why it wanted in. AGR’s Daniel Masters puts the global goat infant formula category at about $5.1 billion, growing at 8% a year, and AGR estimates it would cost more than NZ$600 million to recreate what DGC’s owners have built on farm and in Hamilton. That is not the language of a distressed rescue. It is the language of an investor buying into a hard-to-replicate asset.
For other farmer-owned businesses wrestling with how to fund growth, the structure matters as much as the cheque. Outside capital and owner control are not mutually exclusive.
Back from losing everything
The deal looks sharper against how close DGC came to the edge. In 2025, the co-op laid out the damage: pre-pandemic, 55 to 60% of sales went to China, around half through the daigou personal-shopper channel that vanished when borders shut. It then failed its SAMR registration, required to legally export infant formula to China. “Between those two events, which happened in the course of two and a half and three years, we lost all of our infant formula sales,” Hulbert said at the time. Pivoting to selling milk powder as a non-certified ingredient let the co-op pay down $18 million of debt.
The pain flowed straight to the farm gate, with suppliers rationed through the downturn. The recovery is now visible in the payout, which has climbed from $11/kg MS to the $15 to $16/kg MS range. DGC now sells into around 30 countries, a deliberate hedge against ever again having half its business riding on one border.
Science is the moat
What separates DGC from a commodity processor is evidence. The GIraFFE study, published in Clinical Nutrition and involving more than 2,100 infants in Poland and Spain, found DGC’s whole goat milk formula cut eczema risk by 64% in babies with a parental history of atopic dermatitis, and 34% overall, versus standard cow milk formula. The research was co-funded through the CAPRINZ Primary Growth Partnership with MPI, and another study run by LMU Munich is tracking 2,300 babies from birth to age five.
Clinical data is what lets a premium price hold. Anyone can claim their milk is special. Few can prove it in a peer-reviewed trial.
The road in is long and expensive
The RNZ framing of an expansion “to” China and the US runs ahead of reality. China infant formula re-entry is targeted for 2028 to 2029 and still hinges on SAMR registration. The US, as the 2025 strategy acknowledged, means facing a 31% tariff and a US$4 million FDA-approved clinical trial. “US babies seem to be, for some reason, quite unique to any other baby in the world, so you’ve got to do a clinical trial,” Hulbert told The Post wryly.
That is precisely why patient capital matters. Premium nutrition is a multi-year regulatory project, not a container booking. And the demand logic holds even as birth rates fall. As Hulbert put it, young families in China “may be having fewer babies… but they are spending more on them.” The play is wallet share per baby, not headcount.
Where the growth actually is
Scale helps put this in context. In December 2025, MPI forecast infant formula exports of $2.21 billion for the year to June 2026, up from $2.09 billion, while total dairy export revenue was tipped to rise just 1% to $27.4 billion. Formula is growing faster than the bulk business around it.
The lesson for exporters is not complicated. Concentration nearly killed DGC. Diversification, hard science and capital that respects ownership brought it back. The next test arrives over the next three years, when SAMR registration and an FDA trial decide whether the co-op’s best market access is still ahead of it. On the evidence so far, the bet looks well placed.
Sources
- RNZ: NZ goat formula co-operative expands to China, United States (2026-10-05)
- Farmers Weekly: Dairy Goat Co-operative secures US investment (2026-09-29)
- Farmers Weekly: Dairy Goat Co-operative sets out new strategy after rough few years (2025-08-20)
- Farmers Weekly: Europe-based study validates NZ goat milk claims (2026-06-16)
- Waikato Times: Light at the end of the tunnel for goat farmers
- The Post: $50 tin of formula changed family’s life and helped build global goat milk business (2026-08-08)
- MPI: Caprine Innovations NZ (CAPRINZ)
- MPI: Situation and Outlook for Primary Industries December 2025 (2025-12)
Join the discussion
Add useful context, ask a good question, or challenge an idea — keep it specific and respectful.